Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance Optimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND...
VANCOUVER, British Columbia, Sept. 20, 2022 – Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce that Mr. Kenneth Mushinski has agreed to join the Board of Directors of Anfield as non-Executive...
TORONTO, Sept. 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
VANCOUVER, British Columbia, Sept. 15, 2022 – Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce that the TSX Venture Exchange has accepted for listing 125,000,000 common share purchase warrants...
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University...
Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substance Clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in second half of September 2022 Genvion...
